Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
11.0M
Short interest
settlement 2026-10-15
13.5
Days to cover
-0.7 days vs prior
75.2%
Short share of volume
2026-11-02
997
Fails to deliver
settlement 2026-10-07
Tue 3 Nov
Next earnings
estimated date
-$28.8M
Insider flow, 90 days
0 buys, 20 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in RYTM is 11,003,490 shares, up 715,679 shares over the last month. Over the last 48 readings it ranged from 4,514,524 shares (31 July 2025) to 11,003,490 shares (15 October 2026). The latest reading sits at the top of that range. At the reported average volume of 816K shares a day that is 13.5 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/rytm" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 11,003,490 | +2.2% | 816,276 | 13.48 |
| 2026-09-30 | 10,767,698 | +4.7% | 761,706 | 14.14 |
| 2026-09-15 | 10,287,811 | -0.1% | 512,774 | 20.06 |
| 2026-08-31 | 10,303,031 | +1.5% | 470,672 | 21.89 |
| 2026-08-14 | 10,154,327 | +7.6% | 829,841 | 12.24 |
| 2026-07-31 | 9,440,417 | -1.4% | 583,684 | 16.17 |
| 2026-07-15 | 9,574,527 | -0.9% | 696,954 | 13.74 |
| 2026-06-30 | 9,665,089 | +20.7% | 1,275,960 | 7.57 |
| 2026-06-15 | 8,005,303 | +1.2% | 691,418 | 11.58 |
| 2026-05-29 | 7,911,004 | -4.5% | 535,388 | 14.78 |
| 2026-05-15 | 8,282,367 | +2.8% | 1,000,436 | 8.28 |
| 2026-04-30 | 8,057,652 | +2.9% | 553,925 | 14.55 |
| 2026-04-15 | 7,830,912 | +2.7% | 611,253 | 12.81 |
| 2026-03-31 | 7,624,913 | +16.7% | 1,284,776 | 5.93 |
| 2026-03-13 | 6,535,847 | +3.4% | 861,136 | 7.59 |
| 2026-02-27 | 6,321,762 | +5.0% | 694,357 | 9.10 |
| 2026-02-13 | 6,022,578 | -3.5% | 762,478 | 7.90 |
| 2026-01-30 | 6,237,463 | -0.8% | 528,760 | 11.80 |
| 2026-01-15 | 6,285,002 | +1.4% | 636,899 | 9.87 |
| 2025-12-31 | 6,200,378 | +11.1% | 771,443 | 8.04 |
| 2025-12-15 | 5,581,124 | +1.1% | 1,121,309 | 4.98 |
| 2025-11-28 | 5,518,605 | +0.3% | 647,265 | 8.53 |
| 2025-11-14 | 5,502,046 | +5.2% | 785,650 | 7.00 |
| 2025-10-31 | 5,230,596 | -6.2% | 566,004 | 9.24 |
| 2025-10-15 | 5,574,246 | -0.1% | 528,085 | 10.56 |
| 2025-09-30 | 5,578,461 | +6.8% | 712,661 | 7.83 |
| 2025-09-15 | 5,220,961 | +5.0% | 609,141 | 8.57 |
| 2025-08-29 | 4,969,794 | +6.3% | 507,237 | 9.80 |
| 2025-08-15 | 4,674,524 | +3.5% | 627,363 | 7.45 |
| 2025-07-31 | 4,514,524 | -5.7% | 545,785 | 8.27 |
| 2025-07-15 | 4,789,385 | -1.3% | 1,374,400 | 3.48 |
| 2025-06-30 | 4,853,861 | +2.0% | 569,352 | 8.53 |
| 2025-06-13 | 4,757,385 | -0.4% | 588,666 | 8.08 |
| 2025-05-30 | 4,775,505 | -5.8% | 516,227 | 9.25 |
| 2025-05-15 | 5,070,846 | +4.5% | 727,408 | 6.97 |
| 2025-04-30 | 4,852,888 | -5.0% | 636,146 | 7.63 |
| 2025-04-15 | 5,108,787 | +9.7% | 1,234,311 | 4.14 |
| 2025-03-31 | 4,656,313 | -1.1% | 523,048 | 8.90 |
| 2025-03-14 | 4,710,022 | -8.5% | 561,590 | 8.39 |
| 2025-02-28 | 5,145,240 | -4.9% | 568,315 | 9.05 |
| 2025-02-14 | 5,410,357 | +5.5% | 399,279 | 13.55 |
| 2025-01-31 | 5,127,767 | -6.0% | 471,586 | 10.87 |
| 2025-01-15 | 5,453,889 | +3.6% | 550,151 | 9.91 |
| 2024-12-31 | 5,265,779 | -9.4% | 583,471 | 9.02 |
| 2024-12-13 | 5,809,632 | -8.8% | 470,052 | 12.36 |
| 2024-11-29 | 6,367,381 | -5.1% | 522,467 | 12.19 |
| 2024-11-15 | 6,710,030 | -19.7% | 930,268 | 7.21 |
| 2024-10-31 | 8,360,239 | -1.2% | 311,330 | 26.85 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of RYTM volume is 75.2%, up 30.1 points over the last five sessions. Over the last 30 readings it ranged from 30.4% (5 October 2026) to 84.2% (20 October 2026). The latest reading is 13.2 points above the 30-session average of 62.0%, on 889K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 669K | 889K | 75.2% | 0 |
| 2026-10-30 | 97K | 139K | 70.2% | 0 |
| 2026-10-29 | 204K | 320K | 63.8% | 149 |
| 2026-10-28 | 154K | 265K | 58.2% | 0 |
| 2026-10-27 | 97K | 141K | 68.7% | 296 |
| 2026-10-26 | 50K | 111K | 45.1% | 0 |
| 2026-10-23 | 128K | 214K | 59.8% | 0 |
| 2026-10-22 | 99K | 190K | 51.9% | 0 |
| 2026-10-21 | 174K | 233K | 74.5% | 1 |
| 2026-10-20 | 374K | 444K | 84.2% | 0 |
| 2026-10-19 | 84K | 134K | 62.7% | 0 |
| 2026-10-16 | 98K | 136K | 71.8% | 2 |
| 2026-10-15 | 99K | 160K | 62.2% | 0 |
| 2026-10-14 | 121K | 218K | 55.2% | 0 |
| 2026-10-13 | 203K | 280K | 72.4% | 1,622 |
| 2026-10-12 | 72K | 162K | 44.3% | 40 |
| 2026-10-09 | 607K | 804K | 75.5% | 0 |
| 2026-10-08 | 158K | 407K | 38.9% | 0 |
| 2026-10-07 | 97K | 242K | 40.3% | 0 |
| 2026-10-06 | 315K | 446K | 70.5% | 0 |
| 2026-10-05 | 134K | 439K | 30.4% | 0 |
| 2026-10-02 | 91K | 169K | 54.1% | 0 |
| 2026-10-01 | 97K | 211K | 45.7% | 32 |
| 2026-09-30 | 157K | 223K | 70.2% | 0 |
| 2026-09-29 | 191K | 294K | 65.1% | 0 |
| 2026-09-28 | 304K | 387K | 78.7% | 4 |
| 2026-09-25 | 304K | 462K | 65.9% | 0 |
| 2026-09-24 | 222K | 318K | 69.7% | 240 |
| 2026-09-23 | 208K | 287K | 72.3% | 0 |
| 2026-09-22 | 102K | 164K | 62.1% | 3 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 7 October 2026, the fails-to-deliver balance in RYTM is 997 shares, down 16,172 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (23 September 2026) to 44,084 shares (5 August 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-07 | 997 | $90.77 | $90K |
| 2026-10-05 | 17,169 | $92.83 | $1.6M |
| 2026-09-30 | 43 | $95.71 | $4K |
| 2026-09-23 | 2 | $99.27 | $199 |
| 2026-08-26 | 3,997 | $113.35 | $453K |
| 2026-08-06 | 12,142 | $110.71 | $1.3M |
| 2026-08-05 | 44,084 | $105.78 | $4.7M |
| 2026-07-31 | 11,125 | $105.74 | $1.2M |
| 2026-07-30 | 68 | $106.53 | $7K |
| 2026-07-22 | 527 | $106.60 | $56K |
| 2026-07-17 | 328 | $106.09 | $35K |
| 2026-07-14 | 4 | $107.49 | $430 |
| 2026-06-29 | 22,261 | $109.84 | $2.4M |
| 2026-06-24 | 160 | $106.19 | $17K |
| 2026-06-22 | 9 | $96.79 | $871 |
| 2026-06-18 | 23 | $95.83 | $2K |
| 2026-06-16 | 242 | $89.70 | $22K |
| 2026-06-15 | 23 | $88.38 | $2K |
| 2026-06-12 | 6 | $87.66 | $526 |
| 2026-06-09 | 17 | $85.93 | $1K |
| 2026-06-08 | 2,985 | $86.40 | $258K |
| 2026-06-03 | 13 | $84.35 | $1K |
| 2026-06-02 | 13 | $87.87 | $1K |
| 2026-05-27 | 13 | $89.82 | $1K |
| 2026-05-22 | 5 | $90.19 | $451 |
| 2026-05-21 | 11 | $90.64 | $997 |
| 2026-05-18 | 233 | $90.52 | $21K |
| 2026-05-14 | 15 | $93.72 | $1K |
| 2026-05-12 | 9,222 | $87.39 | $806K |
| 2026-05-11 | 35 | $94.17 | $3K |
Insider trades
SEC Form 4, newest first. JSONInsiders at RYTM reported 20 open-market sells worth $28.8M in the last 90 days and no open-market buys. Latest filing: Meeker David P (President and CEO) on 2026-09-14.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-14 | Meeker David P | President and CEO | Sell | 2K | $105.19 | $242K | 239K |
| 2026-09-14 | Meeker David P | President and CEO | Sell | 2K | $104.55 | $190K | 242K |
| 2026-09-14 | Meeker David P | President and CEO | Sell | 9K | $103.43 | $900K | 243K |
| 2026-09-14 | Meeker David P | President and CEO | Sell | 31K | $102.35 | $3.1M | 252K |
| 2026-09-14 | Meeker David P | President and CEO | Sell | 6K | $101.75 | $655K | 283K |
| 2026-09-14 | Meeker David P | President and CEO | Exercise or conversion | 50K | $6.05 | $303K | 289K |
| 2026-08-31 | Smith Hunter C | Chief Financial Officer | Sell | 28K | $106.20 | $3.0M | 114K |
| 2026-08-31 | Smith Hunter C | Chief Financial Officer | Sell | 12K | $105.37 | $1.2M | 142K |
| 2026-08-31 | Smith Hunter C | Chief Financial Officer | Sell | 23K | $104.59 | $2.4M | 154K |
| 2026-08-31 | Smith Hunter C | Chief Financial Officer | Exercise or conversion | 57K | $25.79 | $1.5M | 177K |
| 2026-08-13 | Shulman Joseph | Chief Technical Officer | Sell | 5K | $119.75 | $608K | 16K |
| 2026-08-13 | Shulman Joseph | Chief Technical Officer | Exercise or conversion | 2K | $6.80 | $14K | 21K |
| 2026-08-13 | Garfield Alastair | Chief Scientific Officer | Sell | 800 | $119.17 | $95K | 2K |
| 2026-08-13 | Garfield Alastair | Chief Scientific Officer | Sell | 3K | $118.28 | $402K | 3K |
| 2026-08-13 | Garfield Alastair | Chief Scientific Officer | Sell | 2K | $117.08 | $182K | 6K |
| 2026-08-13 | Garfield Alastair | Chief Scientific Officer | Sell | 2K | $116.11 | $233K | 8K |
| 2026-08-13 | Lee Jennifer Kayden | EVP, Head of North America | Sell | 76K | $117.38 | $8.9M | 0 |
| 2026-08-13 | Lee Jennifer Kayden | EVP, Head of North America | Exercise or conversion | 22K | $6.80 | $147K | 76K |
| 2026-08-13 | Lee Jennifer Kayden | EVP, Head of North America | Exercise or conversion | 35K | $24.29 | $850K | 54K |
| 2026-08-12 | Mazabraud Yann | EVP, Head of International | Sell | 17K | $117.47 | $2.0M | 56K |
| 2026-08-12 | Mazabraud Yann | EVP, Head of International | Sell | 18K | $116.49 | $2.1M | 73K |
| 2026-08-12 | Mazabraud Yann | EVP, Head of International | Sell | 15K | $115.43 | $1.7M | 91K |
| 2026-08-12 | Mazabraud Yann | EVP, Head of International | Sell | 4K | $114.70 | $413K | 106K |
| 2026-08-12 | Mazabraud Yann | EVP, Head of International | Sell | 1K | $112.86 | $113K | 109K |
| 2026-08-12 | Mazabraud Yann | EVP, Head of International | Sell | 2K | $111.80 | $257K | 110K |
| 2026-08-12 | Mazabraud Yann | EVP, Head of International | Exercise or conversion | 47K | $6.80 | $317K | 113K |
| 2026-07-01 | Garfield Alastair | Chief Scientific Officer | Tax withholding | 2K | $110.41 | $237K | 10K |
| 2026-07-01 | Garfield Alastair | Chief Scientific Officer | Exercise or conversion | 4K | price not stated in the filing | not stated | 12K |
| 2026-06-23 | GOOD JENNIFER L | Director | Exercise or conversion | 5K | price not stated in the filing | not stated | 12K |
| 2026-06-23 | Arbuckle Stuart A | Director | Exercise or conversion | 5K | price not stated in the filing | not stated | 12K |
| 2026-06-23 | TETRAULT LYNN A. | Director | Exercise or conversion | 5K | price not stated in the filing | not stated | 12K |
| 2026-06-23 | MCGIRR DAVID W J | Director | Exercise or conversion | 5K | price not stated in the filing | not stated | 12K |
| 2026-06-23 | JEAN CHRISTOPHE | Director | Exercise or conversion | 5K | price not stated in the filing | not stated | 12K |
| 2026-06-22 | TETRAULT LYNN A. | Director | Exercise or conversion | 37K | $28.27 | $1.0M | 44K |
| 2026-06-22 | TETRAULT LYNN A. | Director | Sell | 37K | $100.32 | $3.7M | 7K |
| 2026-05-18 | Smith Hunter C | Chief Financial Officer | Exercise or conversion | 3K | $17.87 | $54K | 120K |
| 2026-05-15 | German Christopher Paul | Corporate Controller & CAO | Sell | 5K | $92.21 | $428K | 0 |
| 2026-05-15 | German Christopher Paul | Corporate Controller & CAO | Exercise or conversion | 1K | $17.97 | $25K | 5K |
| 2026-05-15 | German Christopher Paul | Corporate Controller & CAO | Exercise or conversion | 1K | $49.23 | $66K | 3K |
| 2026-05-15 | German Christopher Paul | Corporate Controller & CAO | Exercise or conversion | 2K | $56.69 | $96K | 2K |
| 2026-04-01 | Mazabraud Yann | EVP, Head of International | Exercise or conversion | 13K | price not stated in the filing | not stated | 66K |
| 2026-03-12 | Mathers Edward T | Director | Other transaction | 4K | $0.00 | $0 | 14K |
| 2026-03-04 | German Christopher Paul | Corporate Controller & CAO | Sell | 6K | $89.56 | $503K | 160 |
| 2026-03-04 | German Christopher Paul | Corporate Controller & CAO | Exercise or conversion | 2K | $17.97 | $27K | 6K |
| 2026-03-02 | Smith Hunter C | Chief Financial Officer | Exercise or conversion | 6K | $6.80 | $41K | 117K |
| 2026-03-02 | Mathers Edward T | Director | Other transaction | 4K | $0.00 | $0 | 10K |
| 2026-03-01 | German Christopher Paul | Corporate Controller & CAO | Tax withholding | 342 | $94.94 | $32K | 4K |
| 2026-03-01 | German Christopher Paul | Corporate Controller & CAO | Exercise or conversion | 1K | price not stated in the filing | not stated | 5K |
| 2026-02-19 | Smith Hunter C | Chief Financial Officer | Sell | 585 | $103.28 | $60K | 111K |
| 2026-02-19 | Smith Hunter C | Chief Financial Officer | Sell | 800 | $102.10 | $82K | 111K |
| 2026-02-19 | Smith Hunter C | Chief Financial Officer | Sell | 2K | $100.92 | $171K | 112K |
| 2026-02-19 | Smith Hunter C | Chief Financial Officer | Sell | 1K | $100.27 | $131K | 114K |
| 2026-02-17 | Smith Hunter C | Chief Financial Officer | Sell | 200 | $103.84 | $21K | 115K |
| 2026-02-17 | Smith Hunter C | Chief Financial Officer | Sell | 1K | $103.00 | $110K | 115K |
| 2026-02-17 | Smith Hunter C | Chief Financial Officer | Sell | 900 | $101.70 | $92K | 116K |
| 2026-02-17 | Smith Hunter C | Chief Financial Officer | Sell | 200 | $100.52 | $20K | 117K |
| 2026-02-17 | Smith Hunter C | Chief Financial Officer | Sell | 1K | $99.42 | $119K | 117K |
| 2026-02-14 | Mazabraud Yann | EVP, Head of International | Exercise or conversion | 10K | price not stated in the filing | not stated | 53K |
| 2026-02-12 | Smith Hunter C | Chief Financial Officer | Sell | 100 | $100.10 | $10K | 118K |
| 2026-02-12 | Smith Hunter C | Chief Financial Officer | Sell | 800 | $98.99 | $79K | 119K |
| 2026-02-12 | Smith Hunter C | Chief Financial Officer | Sell | 400 | $97.67 | $39K | 119K |
| 2026-02-12 | Smith Hunter C | Chief Financial Officer | Sell | 292 | $96.26 | $28K | 120K |
| 2026-02-11 | Smith Hunter C | Chief Financial Officer | Sell | 100 | $100.85 | $10K | 120K |
| 2026-02-11 | Smith Hunter C | Chief Financial Officer | Sell | 400 | $99.44 | $40K | 120K |
| 2026-02-11 | Smith Hunter C | Chief Financial Officer | Sell | 2K | $98.37 | $223K | 121K |
| 2026-02-10 | Smith Hunter C | Chief Financial Officer | Sell | 100 | $104.76 | $10K | 123K |
| 2026-02-10 | Smith Hunter C | Chief Financial Officer | Sell | 700 | $103.68 | $73K | 123K |
| 2026-02-10 | Smith Hunter C | Chief Financial Officer | Sell | 2K | $102.66 | $196K | 124K |
| 2026-02-05 | Smith Hunter C | Chief Financial Officer | Sell | 3K | $106.06 | $359K | 126K |
| 2026-02-04 | Smith Hunter C | Chief Financial Officer | Sell | 747 | $107.67 | $80K | 129K |
| 2026-02-04 | Smith Hunter C | Chief Financial Officer | Sell | 1K | $106.60 | $107K | 130K |
| 2026-02-04 | Smith Hunter C | Chief Financial Officer | Sell | 2K | $104.74 | $157K | 131K |
| 2026-02-01 | Cramer Pamela J. | Chief Human Resources Officer | Tax withholding | 5K | $108.99 | $516K | 29K |
| 2026-02-01 | Cramer Pamela J. | Chief Human Resources Officer | Exercise or conversion | 13K | price not stated in the filing | not stated | 34K |
| 2026-02-01 | Garfield Alastair | Chief Scientific Officer | Tax withholding | 2K | $108.99 | $221K | 8K |
| 2026-02-01 | Garfield Alastair | Chief Scientific Officer | Exercise or conversion | 7K | price not stated in the filing | not stated | 10K |
| 2026-02-01 | German Christopher Paul | Corporate Controller & CAO | Tax withholding | 1K | $108.99 | $124K | 3K |
| 2026-02-01 | German Christopher Paul | Corporate Controller & CAO | Exercise or conversion | 4K | price not stated in the filing | not stated | 5K |
| 2026-02-01 | Lee Jennifer Kayden | EVP, Head of North America | Exercise or conversion | 23K | price not stated in the filing | not stated | 28K |
| 2026-02-01 | Lee Jennifer Kayden | EVP, Head of North America | Tax withholding | 9K | $108.99 | $1.0M | 19K |
| 2026-02-01 | Meeker David P | President and CEO | Exercise or conversion | 69K | price not stated in the filing | not stated | 271K |
| 2026-02-01 | Meeker David P | President and CEO | Tax withholding | 32K | $108.99 | $3.4M | 239K |
| 2026-02-01 | Shulman Joseph | Chief Technical Officer | Exercise or conversion | 17K | price not stated in the filing | not stated | 25K |
| 2026-02-01 | Shulman Joseph | Chief Technical Officer | Tax withholding | 7K | $108.99 | $709K | 19K |
| 2026-02-01 | Smith Hunter C | Chief Financial Officer | Exercise or conversion | 26K | price not stated in the filing | not stated | 143K |
| 2026-02-01 | Smith Hunter C | Chief Financial Officer | Tax withholding | 11K | $108.99 | $1.2M | 132K |
| 2026-02-01 | Mazabraud Yann | EVP, Head of International | Exercise or conversion | 6K | price not stated in the filing | not stated | 43K |
| 2025-12-11 | Cramer Pamela J. | Chief Human Resources Officer | Sell | 3K | $111.00 | $372K | 21K |
| 2025-12-11 | Cramer Pamela J. | Chief Human Resources Officer | Exercise or conversion | 3K | $27.35 | $92K | 24K |
| 2025-11-20 | Cramer Pamela J. | Chief Human Resources Officer | Sell | 3K | $105.00 | $352K | 21K |
| 2025-11-20 | Cramer Pamela J. | Chief Human Resources Officer | Exercise or conversion | 3K | $27.35 | $92K | 24K |
| 2025-11-10 | Cramer Pamela J. | Chief Human Resources Officer | Sell | 4K | $100.00 | $352K | 21K |
| 2025-11-10 | Cramer Pamela J. | Chief Human Resources Officer | Exercise or conversion | 4K | $6.80 | $24K | 24K |
| 2025-11-07 | Cramer Pamela J. | Chief Human Resources Officer | Sell | 19K | $98.82 | $1.9M | 21K |
| 2025-11-07 | Cramer Pamela J. | Chief Human Resources Officer | Exercise or conversion | 11K | $6.80 | $72K | 40K |
| 2025-11-07 | Cramer Pamela J. | Chief Human Resources Officer | Exercise or conversion | 9K | $19.02 | $167K | 30K |
| 2025-10-30 | Shulman Joseph | Chief Technical Officer | Sell | 10K | $115.24 | $1.1M | 9K |
| 2025-10-30 | Shulman Joseph | Chief Technical Officer | Exercise or conversion | 10K | $30.66 | $299K | 18K |
| 2025-10-28 | Shulman Joseph | Chief Technical Officer | Sell | 3K | $115.01 | $324K | 9K |
| 2025-10-28 | Shulman Joseph | Chief Technical Officer | Exercise or conversion | 721 | $30.66 | $22K | 11K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON20 Form 144 notices on file for RYTM worth $51.5M at the prices reported; 8 in the last 90 days worth $30.5M. Latest: David Meeker filed on 2026-09-14 to sell 50,000 shares ($5.2M) from 2026-09-14.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-14 | David MeekerDirector, Officer | 50K | $5.2M | 0.073% | 2026-09-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-31 | HUNTER SMITHOfficer | 63K | $6.7M | 0.091% | 2026-08-31 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-13 | JOSEPH J SHULMANOfficer | 5K | $597K | 0.007% | 2026-08-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-13 | Jennifer Kayden LeeOfficer | 76K | $8.9M | 0.110% | 2026-08-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-13 | ALASTAIR GARFIELDOfficer | 8K | $913K | 0.011% | 2026-08-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-12 | YANN MAZABRAUDOfficer | 57K | $6.4M | 0.083% | 2026-08-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-11 | PAMELA CRAMEROfficer | 11K | $1.3M | 0.017% | 2026-08-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-10 | PAMELA CRAMEROfficer | 4K | $407K | 0.005% | 2026-08-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-22 | LYNN TETRAULTDirector | 37K | $3.6M | 0.054% | 2026-06-22 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-04 | CAMILLE L BEDROSIANDirector | 65K | $5.8M | 0.095% | 2026-03-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-03 | CAMILLE L BEDROSIANDirector | 35K | $3.2M | 0.052% | 2026-03-03 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-05 | HUNTER SMITHOfficer | 18K | $2.0M | 0.028% | 2026-02-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-04 | HUNTER SMITHOfficer | 3K | $352K | 0.005% | 2026-02-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-11 | PAMELA CRAMEROfficer | 3K | $351K | 0.005% | 2025-12-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-20 | PAMELA CRAMEROfficer | 3K | $346K | 0.005% | 2025-11-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-10 | PAMELA CRAMEROfficer | 4K | $353K | 0.005% | 2025-11-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-07 | PAMELA CRAMEROfficer | 19K | $1.9M | 0.029% | 2025-11-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-30 | JOSEPH SHULMANOfficer | 10K | $1.1M | 0.015% | 2025-10-30 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-28 | JOSEPH SHULMANOfficer | 3K | $314K | 0.004% | 2025-10-28 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-16 | JOSEPH SHULMANOfficer | 14K | $1.6M | 0.022% | 2025-10-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON9 holders report 5% or more of RYTM in their latest filing, all on Schedule 13G (passive). The largest reported stake is RA Capital Management, L.P. at 9.9% of the class (6,666,837 shares), filed 2026-02-17 for an event on 2025-12-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-13 | 13G | JPMORGAN CHASE & CO.parent holding company | 3.6M | 5.1% | 2026-09-30 |
| 2026-05-15 | 13G/Ano. 2 | Perceptive Advisors LLCinvestment adviser | 3.5M | 5.1% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Joseph Edelmanindividual | 3.5M | 5.1% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Perceptive Life Sciences Master Fund, Ltd.corporation | 2.8M | 4.1% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Perceptive Capital Solutions Holdings LPpartnership | 729K | 1.1% | 2026-03-31 |
| 2026-04-30 | 13G | Vanguard Capital Managementinvestment adviser | 3.4M | 5.0% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 3 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-17 | 13G/Ano. 8 | RA Capital Management, L.P.investment adviser, partnership | 6.7M | 9.9% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 8 | Peter Kolchinskyparent holding company, individual | 6.7M | 9.9% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 8 | Rajeev Shahparent holding company, individual | 6.7M | 9.9% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 8 | RA Capital Healthcare Fund, L.P.partnership | 6.7M | 9.9% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 12 | PRIMECAP MANAGEMENT CO/CA/investment adviser | 3.5M | 5.2% | 2025-12-31 |
13F holders
Tracked managers holding RYTM at their latest 13F. JSON8 of the 30 tracked managers held RYTM at their latest 13F, $262.1M in total at quarter-end prices. Citadel Advisors is the largest at $140.3M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 6 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 1.3M | $140.3M | 0.02% | -155K |
| Point72 Asset Management | 2026-06-30 | 414K | $46.0M | 0.05% | -433K |
| Millennium Management | 2026-06-30 | 317K | $35.2M | 0.01% | -135K |
| Duquesne Family Office | 2026-06-30 | 204K | $22.6M | 0.43% | new |
| Renaissance Technologies | 2026-06-30 | 68K | $7.6M | 0.01% | -190K |
| AQR Capital Management | 2026-06-30 | 59K | $6.6M | 0.00% | -71 |
| D. E. Shaw & Co. | 2026-06-30 | 30K | $3.3M | 0.00% | -2K |
| Two Sigma Investments | 2026-06-30 | 5K | $511K | 0.00% | +300 |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Rhythm Pharmaceuticals reported revenue of $71.3M, up 46.9% from the same quarter a year earlier, and net loss of $49.3M (-0.73 diluted EPS). In FY 2025 it generated -$115.7M of operating cash flow. As of 2026-06-30, cash was $65.6M against $93.4M of debt.
- Cash
- $65.6M
- Debt
- $93.4M
- Equity
- $103.0M
- Total assets
- $437.3M
- Shares outstanding
- 68,852,082
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $71.3M | -$49.3M | -69.2% | -0.73 |
| Q1 FY 2026 | 2026-03-31 | $60.1M | -$55.6M | -92.6% | -0.83 |
| Q4 FY 2025derived | 2025-12-31 | $57.3M | -$47.5M | -83.0% | n/a |
| Q3 FY 2025 | 2025-09-30 | $51.3M | -$52.9M | -103.1% | -0.82 |
| Q2 FY 2025 | 2025-06-30 | $48.5M | -$46.6M | -96.1% | -0.75 |
| Q1 FY 2025 | 2025-03-31 | $32.7M | -$49.5M | -151.4% | -0.81 |
| Q4 FY 2024derived | 2024-12-31 | $41.8M | -$43.3M | -103.6% | n/a |
| Q3 FY 2024 | 2024-09-30 | $33.3M | -$43.6M | -131.2% | -0.73 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $189.8M | -$196.5M | -$115.7M | $953K | n/a | n/a |
| FY 2024 | 2024-12-31 | $130.1M | -$260.6M | -$113.9M | $0 | n/a | n/a |
| FY 2023 | 2023-12-31 | $77.4M | -$184.7M | -$136.2M | $47K | n/a | n/a |
| FY 2022 | 2022-12-31 | $23.6M | -$181.1M | -$173.4M | $281K | n/a | n/a |
| FY 2021 | 2021-12-31 | $3.2M | -$69.6M | -$146.0M | $434K | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-01 from the cover page.
What this page is
Rhythm Pharmaceuticals in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Rhythm Pharmaceuticals (RYTM), SEC CIK 1649904, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-07.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-14.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-13.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-04.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-14.JSON and CSV
- Company record
- EDGAR filing index for CIK 1649904Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of RYTM is sold short?
11,003,490 shares were held short at the 2026-10-15 settlement, 13.5 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is RYTM's daily short volume?
On 2026-11-02, 668,628 of the 889,052 RYTM shares reported to FINRA were sold short, 75.2% of the day's reported volume. Short volume is a flow for one day, not a position.
Does RYTM have fails to deliver?
The SEC's latest file shows 997 RYTM shares failed to deliver at settlement 2026-10-07. Fails are reported per settlement date and published twice a month with a lag.
Are RYTM insiders buying or selling?
Insiders at RYTM reported 20 open-market sells worth $28.8M in the last 90 days and no open-market buys. Latest filing: Meeker David P (President and CEO) on 2026-09-14.
Have RYTM insiders filed to sell?
20 Form 144 notices on file for RYTM worth $51.5M at the prices reported; 8 in the last 90 days worth $30.5M. Latest: David Meeker filed on 2026-09-14 to sell 50,000 shares ($5.2M) from 2026-09-14.
Who owns 5% or more of RYTM?
9 holders report 5% or more of RYTM in their latest filing, all on Schedule 13G (passive). The largest reported stake is RA Capital Management, L.P. at 9.9% of the class (6,666,837 shares), filed 2026-02-17 for an event on 2025-12-31.
What did RYTM report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Rhythm Pharmaceuticals reported revenue of $71.3M, up 46.9% from the same quarter a year earlier, and net loss of $49.3M (-0.73 diluted EPS). In FY 2025 it generated -$115.7M of operating cash flow. As of 2026-06-30, cash was $65.6M against $93.4M of debt.
Which tracked 13F managers own RYTM?
8 of the 30 tracked 13F managers held RYTM shares at their latest filing, $262.1M in all. The largest: Ken Griffin's Citadel Advisors (1.3M shares, $140.3M), Steve Cohen's Point72 Asset Management (414K shares, $46.0M), Izzy Englander's Millennium Management (317K shares, $35.2M), Stanley Druckenmiller's Duquesne Family Office (204K shares, $22.6M), Renaissance Technologies (68K shares, $7.6M), Cliff Asness's AQR Capital Management (59K shares, $6.6M). The table above lists all 8.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.